Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

38 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
HER2-positive breast cancer: ¹⁸F-FDG PET for early prediction of response to trastuzumab plus taxane-based neoadjuvant chemotherapy.
Humbert O, Cochet A, Riedinger JM, Berriolo-Riedinger A, Arnould L, Coudert B, Desmoulins I, Toubeau M, Dygai-Cochet I, Guiu S, Coutant C, Fumoleau P, Brunotte F. Humbert O, et al. Among authors: toubeau m. Eur J Nucl Med Mol Imaging. 2014 Aug;41(8):1525-33. doi: 10.1007/s00259-014-2739-1. Epub 2014 Mar 20. Eur J Nucl Med Mol Imaging. 2014. PMID: 24647576
Baseline diastolic dysfunction as a predictive factor of trastuzumab-mediated cardiotoxicity after adjuvant anthracycline therapy in breast cancer.
Cochet A, Quilichini G, Dygai-Cochet I, Touzery C, Toubeau M, Berriolo-Riedinger A, Coudert B, Cottin Y, Fumoleau P, Brunotte F. Cochet A, et al. Among authors: toubeau m. Breast Cancer Res Treat. 2011 Dec;130(3):845-54. doi: 10.1007/s10549-011-1714-9. Epub 2011 Sep 15. Breast Cancer Res Treat. 2011. PMID: 21918836 Clinical Trial.
Evaluation of breast tumor blood flow with dynamic first-pass 18F-FDG PET/CT: comparison with angiogenesis markers and prognostic factors.
Cochet A, Pigeonnat S, Khoury B, Vrigneaud JM, Touzery C, Berriolo-Riedinger A, Dygai-Cochet I, Toubeau M, Humbert O, Coudert B, Fumoleau P, Arnould L, Brunotte F. Cochet A, et al. Among authors: toubeau m. J Nucl Med. 2012 Apr;53(4):512-20. doi: 10.2967/jnumed.111.096834. Epub 2012 Feb 17. J Nucl Med. 2012. PMID: 22343501 Free article. Clinical Trial.
In newly diagnosed diffuse large B-cell lymphoma, determination of bone marrow involvement with 18F-FDG PET/CT provides better diagnostic performance and prognostic stratification than does biopsy.
Berthet L, Cochet A, Kanoun S, Berriolo-Riedinger A, Humbert O, Toubeau M, Dygai-Cochet I, Legouge C, Casasnovas O, Brunotte F. Berthet L, et al. Among authors: toubeau m. J Nucl Med. 2013 Aug;54(8):1244-50. doi: 10.2967/jnumed.112.114710. Epub 2013 May 14. J Nucl Med. 2013. PMID: 23674577 Free article.
¹⁸F-FDG PET/CT provides powerful prognostic stratification in the primary staging of large breast cancer when compared with conventional explorations.
Cochet A, Dygai-Cochet I, Riedinger JM, Humbert O, Berriolo-Riedinger A, Toubeau M, Guiu S, Coutant C, Coudert B, Fumoleau P, Brunotte F. Cochet A, et al. Among authors: toubeau m. Eur J Nucl Med Mol Imaging. 2014 Mar;41(3):428-37. doi: 10.1007/s00259-013-2595-4. Epub 2013 Nov 7. Eur J Nucl Med Mol Imaging. 2014. PMID: 24196916
Prognostic relevance at 5 years of the early monitoring of neoadjuvant chemotherapy using (18)F-FDG PET in luminal HER2-negative breast cancer.
Humbert O, Berriolo-Riedinger A, Cochet A, Gauthier M, Charon-Barra C, Guiu S, Desmoulins I, Toubeau M, Dygai-Cochet I, Coutant C, Fumoleau P, Brunotte F. Humbert O, et al. Among authors: toubeau m. Eur J Nucl Med Mol Imaging. 2014 Mar;41(3):416-27. doi: 10.1007/s00259-013-2616-3. Epub 2013 Nov 21. Eur J Nucl Med Mol Imaging. 2014. PMID: 24258007
18F-FDG PET-Derived Tumor Blood Flow Changes After 1 Cycle of Neoadjuvant Chemotherapy Predicts Outcome in Triple-Negative Breast Cancer.
Humbert O, Riedinger JM, Vrigneaud JM, Kanoun S, Dygai-Cochet I, Berriolo-Riedinger A, Toubeau M, Depardon E, Lassere M, Tisserand S, Fumoleau P, Brunotte F, Cochet A. Humbert O, et al. Among authors: toubeau m. J Nucl Med. 2016 Nov;57(11):1707-1712. doi: 10.2967/jnumed.116.172759. Epub 2016 Apr 21. J Nucl Med. 2016. PMID: 27103025 Free article. Clinical Trial.
FDG PET/CT for prognostic stratification of patients with metastatic breast cancer treated with first line systemic therapy: Comparison of EORTC criteria and PERCIST.
Depardon E, Kanoun S, Humbert O, Bertaut A, Riedinger JM, Tal I, Vrigneaud JM, Lasserre M, Toubeau M, Berriolo-Riedinger A, Dygai-Cochet I, Fumoleau P, Brunotte F, Cochet A. Depardon E, et al. Among authors: toubeau m. PLoS One. 2018 Jul 16;13(7):e0199529. doi: 10.1371/journal.pone.0199529. eCollection 2018. PLoS One. 2018. PMID: 30011328 Free PMC article.
38 results